Scientists grow powerful line of breast cancer stem cells

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 9
Volume 16
Issue 9

It was a serendipitous discovery, indeed. Tan A. Ince, MD, PhD, of Harvard Medical School, set out to develop a breast cancer cell line with cells that looked more like the actual disease under a microscope and behaved more like cancer cells in patients. Instead, he created a line of extraordinarily potent cancer stem cells

CAMBRIDGE, Massachusetts—It was a serendipitous discovery, indeed. Tan A. Ince, MD, PhD, of Harvard Medical School, set out to develop a breast cancer cell line with cells that looked more like the actual disease under a microscope and behaved more like cancer cells in patients. Instead, he created a line of extraordinarily potent cancer stem cells (Cancer Cell 12:160-170, 2007).

Dr. Ince, working as a postdoctoral researcher in the laboratory of Robert Weinberg, PhD, at the Whitehead Institute for Biomedical Research, developed a new chemically defined culture medium, dubbed WIT. This medium allowed the growth of a type of breast cell that normally dies in culture. Next, he transformed the cells using a retroviral vector to insert three genes: hTERT, the SV40 early region, and H-ras oncogene.

These cancer cells proved to be extremely potent. When Dr. Ince injected more than 100,000 of them into an immune-compromised mouse, the animal rapidly developed huge, lethal tumors.

The researchers repeated the experiment using increasingly lower numbers of cells, down to as few as 100. Even at that level, the cells continued to create tumors that metastasized. This number proved a remarkable contrast to the more than 1 million cells needed to grow a tumor in mice from cancer cells routinely used in experiments.

Dr. Ince then took a single human breast tissue sample, grew and transformed cells from it in both cell lines, and injected them into mice. The cells grown in WIT proved 10,000 times stronger as tumor initiators and the only ones capable of metastasizing.

Related Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content